Shorts Action: Curis Incorporated (NASDAQ:CRIS) on Focus After Report of More Shorts

November 30, 2016 - By Clifton Ray   ·   0 Comments

Shorts Action: Curis Incorporated (NASDAQ:CRIS) on Focus After Report of More Shorts

The stock of Curis Incorporated (NASDAQ:CRIS) registered an increase of 1.68% in short interest. CRIS’s total short interest was 4.11 million shares in November as published by FINRA. Its up 1.68% from 4.04 million shares, reported previously. With 390,600 shares average volume, it will take short sellers 11 days to cover their CRIS’s short positions. The short interest to Curis Incorporated’s float is 4.1%. About 31,020 shares traded hands. Curis, Inc. (NASDAQ:CRIS) has risen 43.93% since April 27, 2016 and is uptrending. It has outperformed by 38.70% the S&P500.

Curis, Inc. is a biotechnology company. The company has a market cap of $418.69 million. The Firm is engaged in the development and commercialization of drug candidates for the treatment of human cancers. It currently has negative earnings. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase (PI3K) enzymes.

Insitutional Activity: The institutional sentiment decreased to 1.21 in 2016 Q2. Its down 0.57, from 1.78 in 2016Q1. The ratio turned negative, as 8 funds sold all Curis, Inc. shares owned while 15 reduced positions. 11 funds bought stakes while 30 increased positions. They now own 67.45 million shares or 4.41% less from 70.56 million shares in 2016Q1.
Moreover, Ameriprise Fincl Inc has 0% invested in Curis, Inc. (NASDAQ:CRIS) for 500,176 shares. Moreover, Voya Inv Mngmt Limited Com has 0% invested in Curis, Inc. (NASDAQ:CRIS) for 55,931 shares. Oxford Asset Management last reported 0% of its portfolio in the stock. Deutsche Natl Bank Ag holds 512,974 shares or 0% of its portfolio. Baker Bros Advsr L P has 2.00 million shares for 0.03% of their US portfolio. Blackrock Inc accumulated 8,844 shares or 0% of the stock. Bridgeway Mgmt Inc last reported 277,725 shares in the company. Amalgamated National Bank has 0% invested in the company for 11,792 shares. Blackrock Advsr Ltd Limited Liability Company last reported 0% of its portfolio in the stock. Tower Limited Liability (Trc) reported 7,157 shares or 0% of all its holdings. Fmr Ltd holds 15.92 million shares or 0% of its portfolio. Blackrock Fund holds 4.59 million shares or 0% of its portfolio. California Employees Retirement Systems holds 0% or 234,400 shares in its portfolio. Tudor Investment Et Al holds 18,963 shares or 0% of its portfolio. Nationwide Fund Advisors reported 75,161 shares or 0% of all its holdings.

Curis, Inc. (NASDAQ:CRIS) Ratings Coverage

Out of 4 analysts covering Curis (NASDAQ:CRIS), 3 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 75% are positive. Curis has been the topic of 6 analyst reports since August 10, 2015 according to StockzIntelligence Inc. Roth Capital maintained the shares of CRIS in a report on Monday, November 9 with “Buy” rating. TH Capital maintained Curis, Inc. (NASDAQ:CRIS) rating on Monday, November 9. TH Capital has “Buy” rating and $5 price target. The firm has “Hold” rating by Zacks given on Tuesday, September 1. Zacks downgraded Curis, Inc. (NASDAQ:CRIS) on Monday, September 21 to “Sell” rating. The rating was initiated by FBR Capital with “Outperform” on Tuesday, August 11.

CRIS Company Profile

Curis, Inc., incorporated on February 14, 2000, is a biotechnology company. The Firm is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.

Another recent and important Curis, Inc. (NASDAQ:CRIS) news was published by Seekingalpha.com which published an article titled: “Curis: One Swallow Doesn’t Make A Summer” on November 22, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Clifton Ray


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>